The report, published Friday by the U.S. Centers for Disease Control and Prevention, said the vaccine’s safety data so far were similar to those seen in clinical trials. But safety checks during vaccine release quickly identified blood clotting events.
“Rare adverse events But most serious in women, large blood clots, along with low platelet counts, were quickly detected by the United States’ vaccine safety monitoring system, ”the CDC researchers wrote in the report. “Monitoring of all common and rare adverse events following exposure to all COVID-19 vaccines, including the Janssen COVID-19 vaccine, is ongoing.”
The new CDC report summarizes the latest vaccine safety data, including 13,725 events reported through the agency’s Vaccine Adverse Event Reporting System. The data showed that 97% of the events were not significant.
In total, there were 17 events consistent with what was described as thrombocytopenia or thrombocytopenia, including 14 with venous sinus thrombosis. Cerebral venous sinus events and three other non-cerebral venous sinus events in women younger than 60 during vaccine discontinuation, according to the report.
The data also included 88 deaths reported after vaccination. Of those deaths, three occurred in patients with venous sinus thrombosis, and CDC researchers wrote that after preliminary investigations were made. “No other deaths were associated with vaccination.”
Increased ‘anxiety-related events’
All of these anxiety-related events preceded a report of thromboembolism with the Janssen vaccine-linked thrombocytopenia syndrome.
In a study published Friday in the CDC’s Morbidity and Mortality Weekly Report, researchers examined data from five vaccination sites that reported increased anxiety-related events, including rates. Rapid heartbeat, tachycardia and fainting following Johnson & Johnson’s Janssen Covid 19 vaccinations, April 7-9.
The researchers summarized 64 anxiety-related events from 8,624 vaccine recipients.The researchers identified the rate of syncope or fainting at 8.2 per 100,000 strokes, 164 times the rate of fainting after vaccination. influenza
All events were reported to the vaccine adverse event reporting system and were not considered “fatal.” According to VAERS, more than half of the reported fainting events occurred in women. For four of the five sites observed, these incidents took place on the first day of the Janssen shot administration.
The study authors point out that because the Janssen Covid-19 vaccine is a single injection, people who fear needles may be more likely to receive this vaccine than one of the two-dose options. Of all fainting cases, 20% of those reported occurred in those who informed the vaccination facility staff that they had a history of needle dislike.
Half of reports of fainting occurred in people 18 to 29 years of age, and injection-induced fainting was more common in adolescents and young adults. Researchers cited similar rates of fainting in human papillomavirus vaccination. Most of which is given to young people, the HPV vaccine has a fainting rate of 7.8 per 100,000.
Researchers say tracking anxiety event rates will be crucial information for healthcare providers as the Covid-19 vaccine reaches more and more young people.
“Anxiety-related events can occur after vaccination,” the study authors write.
“It is important for the vaccine provider to note that adverse events related to anxiety may be reported more frequently after receiving the Janssen COVID-19 vaccine than after influenza vaccination and observing the recipients of the COVID-19 vaccine.” Total 19 for any adverse reaction for at least 15 minutes after vaccination. “The researcher wrote. “As the use of the COVID-19 vaccine extends to younger age groups, providers should note that younger people may be more likely to have post-vaccination anxiety-related events than older adults.”